New York, January 6, 2026, 19:58 (EST) — After-hours
- TMO was flat in extended trade after closing up about 1.6% at $620.72, a fresh 52-week high
- Evercore ISI raised its price target to $650 and kept an Outperform rating
- Investors are watching CEO Marc Casper’s JPMorgan Healthcare Conference slot on Jan. 13 and earnings on Jan. 29
Thermo Fisher Scientific Inc (TMO) shares were little changed in after-hours trading on Tuesday, after the stock closed up 1.56% at $620.72 and logged a new 52-week high. The shares traded between $602.40 and $628.05 during the session as U.S. stocks climbed, while volume topped the 50-day average, MarketWatch data showed.
The rally puts a spotlight on what management says next week at the JPMorgan Healthcare Conference, where CEO Marc Casper is scheduled to speak on Jan. 13 at 11:15 a.m. ET. Investors often use the conference for the first major read on healthcare demand trends each year.
Thermo Fisher on Tuesday announced the first patient enrollment in a new PPD CorEvitas Obesity Registry, an observational study designed to track patients in routine care over time. Such registries generate “real-world evidence” — data collected outside controlled clinical trials — that can be used to assess long-term safety and effectiveness, the company said. “The CorEvitas Obesity Registry represents a major step forward in understanding the use and outcomes” of obesity treatments in everyday practice, said Leslie Harrold, vice president and global head of real-world science and strategy for PPD CorEvitas Clinical Registries. Business Wire
Evercore ISI analyst Vijay Kumar on Jan. 5 raised the firm’s price target on Thermo Fisher to $650 from $610 and kept an Outperform rating, citing recovering end markets and sector rotation that have “set the stage for a 2026 Tools play,” according to a TipRanks report of TheFly. In Wall Street shorthand, “tools” refers to companies that sell lab equipment, diagnostics and related services. TipRanks
The next hard catalyst is earnings. Thermo Fisher has said it will release fourth-quarter and full-year 2025 results before the market opens on Jan. 29 and host a conference call at 8:30 a.m. ET the same day.
Life-sciences tools peers also advanced in Tuesday’s session, with Agilent Technologies up 3.45% and Danaher gaining 0.52%, according to MarketWatch data.
With the shares now above the $611 area that marked Monday’s prior peak, traders will watch whether Thermo Fisher can hold the breakout if volumes fade once conference season begins.
But a push to new highs can leave less room for a cautious tone. Any downbeat read on customer budgets or a slower rebound in research and biopharma spending could trigger profit-taking into the January events.
Next up is Casper’s Jan. 13 presentation at JPMorgan, followed by the bigger test on Jan. 29, when investors will parse guidance and demand commentary line by line.
